ATE261451T1 - Antivirale pyrimidin-nukleosid-analogen - Google Patents

Antivirale pyrimidin-nukleosid-analogen

Info

Publication number
ATE261451T1
ATE261451T1 AT01973778T AT01973778T ATE261451T1 AT E261451 T1 ATE261451 T1 AT E261451T1 AT 01973778 T AT01973778 T AT 01973778T AT 01973778 T AT01973778 T AT 01973778T AT E261451 T1 ATE261451 T1 AT E261451T1
Authority
AT
Austria
Prior art keywords
alkyl
halogens
nucleoside analogue
pyrimidine nucleoside
aryl
Prior art date
Application number
AT01973778T
Other languages
English (en)
Inventor
Christopher Mcguigan
Jan Balzarini
Original Assignee
Univ Cardiff
Rega Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff, Rega Foundation filed Critical Univ Cardiff
Application granted granted Critical
Publication of ATE261451T1 publication Critical patent/ATE261451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01973778T 2000-04-17 2001-04-12 Antivirale pyrimidin-nukleosid-analogen ATE261451T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0009486.2A GB0009486D0 (en) 2000-04-17 2000-04-17 Chemical compounds
PCT/GB2001/001694 WO2001083501A1 (en) 2000-04-17 2001-04-12 Anti-viral pyrimidine nucleoside analogues

Publications (1)

Publication Number Publication Date
ATE261451T1 true ATE261451T1 (de) 2004-03-15

Family

ID=9890100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973778T ATE261451T1 (de) 2000-04-17 2001-04-12 Antivirale pyrimidin-nukleosid-analogen

Country Status (14)

Country Link
US (4) US7820631B2 (de)
EP (1) EP1274713B1 (de)
JP (1) JP4959900B2 (de)
AT (1) ATE261451T1 (de)
AU (1) AU781323B2 (de)
CA (1) CA2403835C (de)
DE (1) DE60102293T2 (de)
DK (1) DK1274713T3 (de)
ES (1) ES2215931T3 (de)
GB (1) GB0009486D0 (de)
NZ (1) NZ521828A (de)
PT (1) PT1274713E (de)
TR (1) TR200400785T4 (de)
WO (1) WO2001083501A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
TWI244924B (en) 1998-01-23 2005-12-11 Newbiotics Inc Enzyme catalyzed therapeutic agents
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
PL2132215T3 (pl) * 2007-02-28 2016-04-29 Univ Alberta Związki do zapobiegania lub leczenia zakażeń wirusowych i sposoby ich stosowania
GB2452556A (en) * 2007-09-07 2009-03-11 Univ Leuven Kath Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
AU2011311847B2 (en) 2010-10-09 2016-06-23 Contravir Pharmaceuticals, Inc. Method of preparation of antiviral compounds and useful intermediates thereof
CN102443032B (zh) * 2010-10-09 2015-07-22 英希比泰克斯公司 制备抗病毒组合物的方法及其中间体的应用
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
GB201111779D0 (en) 2011-07-08 2011-08-24 Univ Cardiff Chemical compounds
EP2755983B1 (de) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituierte carbonyloxymethylphosphoramidatverbindungen und pharmazeutische zusammensetzungen zur behandlung von virusinfektionen
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
EA031301B1 (ru) 2012-05-22 2018-12-28 Иденикс Фармасьютикалз Ллс D-аминокислотные химические соединения для лечения заболеваний печени
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
EP2861611B1 (de) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Uracyl-spirooxetan-nukleoside
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
MX353422B (es) 2012-10-08 2018-01-12 Idenix Pharmaceuticals Llc Análogos de 2'-cloronucleósido para infección por vhc.
EP2909222B1 (de) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-verbrückten nukleoside für hcv-infektion
EP2935304A1 (de) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluor-nukleoside zur behandlung von hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2018035429A1 (en) 2016-08-18 2018-02-22 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
EP0346108A3 (de) 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infektiöse Nukleoside
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6022876A (en) 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9708611D0 (en) * 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
MXPA02000761A (es) 1999-07-22 2002-08-12 Newbiotics Inc Agentes terapeuticos anti-infecciosos catalizados por enzima.
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
EP1758916B1 (de) 2004-06-07 2012-11-21 Anadys Pharmaceuticals, Inc. 3-beta-d-ribofuranosylthiazolo[4,5-d]pyridiminnukleoside und anwendungen davon
GB0609178D0 (en) * 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
GB2452556A (en) * 2007-09-07 2009-03-11 Univ Leuven Kath Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus
GB201111779D0 (en) * 2011-07-08 2011-08-24 Univ Cardiff Chemical compounds

Also Published As

Publication number Publication date
AU781323B2 (en) 2005-05-19
DE60102293T2 (de) 2005-02-17
JP2004506606A (ja) 2004-03-04
JP4959900B2 (ja) 2012-06-27
EP1274713A1 (de) 2003-01-15
US8551965B2 (en) 2013-10-08
PT1274713E (pt) 2004-08-31
US20030148967A1 (en) 2003-08-07
AU9519101A (en) 2001-11-12
US9351970B2 (en) 2016-05-31
CA2403835A1 (en) 2001-11-08
NZ521828A (en) 2005-06-24
US20110015147A1 (en) 2011-01-20
WO2001083501A1 (en) 2001-11-08
TR200400785T4 (tr) 2004-07-21
DE60102293D1 (de) 2004-04-15
EP1274713B1 (de) 2004-03-10
DK1274713T3 (da) 2004-08-02
CA2403835C (en) 2010-01-12
US20160244476A1 (en) 2016-08-25
US20140011764A1 (en) 2014-01-09
ES2215931T3 (es) 2004-10-16
GB0009486D0 (en) 2000-06-07
US7820631B2 (en) 2010-10-26

Similar Documents

Publication Publication Date Title
ATE261451T1 (de) Antivirale pyrimidin-nukleosid-analogen
ATE221543T1 (de) Antivirale pyrimidin-nukleosid-analogen
BG95575A (bg) 3'-(2')-амино-и тиолмодифицирани, свързани с флуоресциращо багрило нуклеозиди,нуклеотиди и олигонуклеотиди и метод за тяхното получаване и приложението им
IL110091A (en) POLYSUBSTITUTED IMIDAZO £4, 5-c| PYRIDIN-4-AMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE249219T1 (de) Antivirale verbindungen
PT91715A (pt) Processo para a preparacao de compostos biciclicos com um sustituite guanidina na posicao 4
EP1165560A4 (de) 2-hydroxy methylcyclopropylidenmethyl purine und -pyrimidine als antiviral wirkstoffe
NZ280616A (en) Antisense oligonucleotide derivatives with antiviral activity
ATE24728T1 (de) 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine ihre herstellung und ihre verwendung.
TH8341EX (th) ส่วนผสมต่อต้านไวรัสและสารประกอบสำหรับสิ่งนั้น
FI956246A (fi) Hiili-asykliset nukleosidijohdannaiset antiviraalisina ja antineoplastisina aineina
AR032573A1 (es) Analogo de nucleosido de pirrolo [2,3-d] pirimidina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274713

Country of ref document: EP